New and Emerging Radiosensitizers and Radioprotectors

  title={New and Emerging Radiosensitizers and Radioprotectors},
  author={Aaron C. Spalding and Theodore S. Lawrence},
  journal={Cancer Investigation},
  pages={444 - 456}
The combination of chemotherapy and radiation has led to clinical breakthroughs in several disease sites, and current work continues to define optimum combinations of proven chemotherapy as well as more recently available, noncytotoxic agents. Administration of systemic therapies allows modulation of radiation response to improve tumor control (radiosensitization) or to prevent normal tissue toxicity (radioprotection). Substantial progress has been made in identifying the targets of standard… 
Improving Gemcitabine-Mediated Radiosensitization Using Molecularly Targeted Therapy: A Review
Two of the most promising targets, described in this review, for improving the efficacy of gemcitabine radiation are epidermal growth factor receptor and checkpoint kinase 1.
Chemical radiosensitizers for use in radiotherapy.
  • P. Wardman
  • Biology, Medicine
    Clinical oncology (Royal College of Radiologists (Great Britain))
  • 2007
Milestones in the use of combined-modality radiation therapy and chemotherapy.
Combined-modality therapy (CMT) has been shown in randomized trials to improve survival, compared with either radiation therapy or chemotherapy alone, in the treatment of high-grade gliomas and locally advanced cancers of the head and neck, lung, esophagus, breast, stomach, pancreas, and rectum.
Radiobiological modifiers in clinical radiation oncology: current reality and future potential.
Current outcomes and limitations of radiobiological modifiers that may selectively enhance the radiosensitivity of tumors as well as parallel techniques that may protect normal tissues from radiation injury are reviewed.
Notch inhibitor: a promising carcinoma radiosensitizer.
There is evidence supporting the use of Notch inhibitors as novel and potent radiosensitizers in cancer therapy, although they exhibit significant and potential side effects.
A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation
VLX600, a novel iron-chelating inhibitor of oxidative phosphorylation, potentiated the effect of radiation in tumor spheroids in a synergistic manner and shows encouraging characteristics for development as a novel radiosensitizer.
Ataxia-telangiectasia mutated and the Mre11-Rad50-NBS1 complex: promising targets for radiosensitization.
The great potential of ATM and MRN complex inhibitors, including telomelysin, as radiosensitizing agents are highlighted.
Enhancing the Efficiency of Targeted Radionuclide Therapy
There is an emerging body of evidence that this could be accomplished through a number of means including; the use of radiation sensitizers, the normalization of tumor vasculature, the selectively enhancement of tumor vascular permeability or theUse of combination therapy with agents that have complementary therapeutic effects.
Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer
There currently exist few randomized data exploring novel radiosensitizers to improve response and it is unclear what the clinical endpoints of such trials should be.


The mechanism of action of radiosensitization of conventional chemotherapeutic agents.
Loss of the S-phase checkpoint in cancer cells may provide the molecular basis for selective killing of tumors compared with normal tissues, and the identification of the enzymatic targets for these drugs offers the potential to develop predictive assays for response and to develop methods of imaging the progress of therapy.
Taxol: a novel radiation sensitizer.
Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation.
In the model, an increase in the therapeutic index was obtained for radiation treatment when either AQ4N or tirapazamine was administered concurrently, and this was in contrast to mitomycin C which had a marked effect on the radiation induced functional deficit.
Schedule-Dependent Pulsed Paclitaxel Radiosensitization for Thoracic Malignancy
It is concluded that pulsed low-dose paclitaxel and radiation is a very effective and well-tolerated regimen for thoracic malignancy.
Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results.
This trial evaluates the rates of early and late rectal toxicities in patients with prostate cancer receiving definitive or adjuvant three-dimensional conformal external beam radiation therapy and concurrent daily endorectal applications of amifostine.
Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results?
Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.
FU chemoradiotherapy maximizes local control and, for some tumor sites, improves survival rates and the introduction of oral prodrug analogs will likely further improve the results of FU therapy in several organ systems, such as the rectum, head and neck, and esophagus.
Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: how much data do we need?
  • C. Crane, D. Sargent
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
Oral UFT is a good candidate for phase III study in combination with radiotherapy, as is its counterpart, capecitabine, approved in the United States for metastatic colorectal cancer when single-agent fluoropyrimidine therapy is indicated.
Taxol sensitizes human astrocytoma cells to radiation.
The results of combined taxol-radiation exposures in the human Grade III astrocytoma cell line, G18, suggest that appropriate combinations of taxol have a more than additive interaction in human tissue culture and may have a role in clinical protocols.
Concomitant chemotherapy and radiation therapy certainly improves local control.
  • J. Cooper, K. Ang
  • Medicine
    International journal of radiation oncology, biology, physics
  • 2005